Felix Hernandez

List of Publications by Citations

Source: https://exaly.com/author-pdf/1798601/felix-hernandez-publications-by-citations.pdf
Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

183 papers	8,858 citations	49 h-index	91 g-index
189 ext. papers	9,946 ext. citations	5.9 avg, IF	6.03 L-index

#	Paper	IF	Citations
183	Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. *EMBO Journal*, **2001**, 20, 27-39	13	670
182	Role of tau protein in both physiological and pathological conditions. *Physiological Reviews*, **2004**, 84, 361-84	47.9	641
181	Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. *Journal of Biological Chemistry*, **2003**, 278, 45937-45	5.4	393
180	Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. *Journal of Neurochemistry*, **2002**, 83, 1529-33	6	291
179	GSK-3□a pivotal kinase in Alzheimer disease. *Frontiers in Molecular Neuroscience*, **2014**, 7, 46	6.1	285
178	Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. *European Journal of Neuroscience*, **2007**, 25, 81-6	3.5	268
177	Tauopathies. *Cellular and Molecular Life Sciences*, **2007**, 64, 2219-33	10.3	226
176	Neuronal induction of the immunoproteasome in Huntington's disease. *Journal of Neuroscience*, **2003**, 23, 11653-61	6.6	218
175	Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. *Journal of Neuroscience*, **2006**, 26, 5083-90	6.6	217
174	GSK3: a possible link between beta amyloid peptide and tau protein. *Experimental Neurology*, **2010**, 223, 322-5	5.7	200
173	FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain. *Molecular and Cellular Neurosciences*, **2001**, 18, 702-14	4.8	176
172	Extracellular tau is toxic to neuronal cells. *FEBS Letters*, **2006**, 580, 4842-50	3.8	169
171	Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. *Journal of Neurochemistry*, **2006**, 99, 1445-55	6	169
170	Distinct priming kinases contribute to differential regulation of collapsin response mediator proteins by glycogen synthase kinase-3 in vivo. *Journal of Biological Chemistry*, **2006**, 281, 16591-8	5.4	167
169	GSK3 and tau: two convergence points in Alzheimer's disease. *Journal of Alzheimer's Disease*, **2013**, 33 Suppl 1, S141-4	4.3	162
168	Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. *Journal of Alzheimer's Disease*, **2003**, 5, 301-8	4.3	159
167	Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease. *Journal of Neuroscience*, **2001**, 21, 8772-81	6.6	136

166	Huntington's disease is a four-repeat tauopathy with tau nuclear rods. *Nature Medicine*, **2014**, 20, 881-5	50.5	135
165	Direct Evidence of Internalization of Tau by Microglia In Vitro and In Vivo. *Journal of Alzheimer's Disease*, **2016**, 50, 77-87	4.3	113
164	Glycogen synthase kinase-3 plays a crucial role in tau exon 10 splicing and intranuclear distribution of SC35. Implications for Alzheimer's disease. *Journal of Biological Chemistry*, **2004**, 279, 3801-6	5.4	103
163	Alpha-helix structure in Alzheimer's disease aggregates of tau-protein. *Biochemistry*, **2002**, 41, 7150-5	3.2	100
162	N-terminal cleavage of GSK-3 by calpain: a new form of GSK-3 regulation. *Journal of Biological Chemistry*, **2007**, 282, 22406-13	5.4	99
161	Role of neuroinflammation in adult neurogenesis and Alzheimer disease: therapeutic approaches. *Mediators of Inflammation*, **2013**, 2013, 260925	4.3	97
160	Cooexpression of FTDP-17 tau and GSK-3beta in transgenic mice induce tau polymerization and neurodegeneration. *Neurobiology of Aging*, **2006**, 27, 1258-68	5.6	96
159	Absence of CX3CR1 impairs the internalization of Tau by microglia. *Molecular Neurodegeneration*, **2017**, 12, 59	19	90
158	GSK-3overexpression causes reversible alterations on postsynaptic densities and dendritic morphology of hippocampal granule neurons in vivo. *Molecular Psychiatry*, **2013**, 18, 451-60	15.1	90
157	Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors. *Expert Review of Neurotherapeutics*, **2010**, 10, 703-10	4.3	90
156	Tau-knockout mice show reduced GSK3-induced hippocampal degeneration and learning deficits. *Neurobiology of Disease*, **2010**, 37, 622-9	7.5	87
155	A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease. *Frontiers in Immunology*, **2020**, 11, 456	8.4	87
154	Inhibition of 26S proteasome activity by huntingtin filaments but not inclusion bodies isolated from mouse and human brain. *Journal of Neurochemistry*, **2006**, 98, 1585-96	6	77
153	Acute polyglutamine expression in inducible mouse model unravels ubiquitin/proteasome system impairment and permanent recovery attributable to aggregate formation. *Journal of Neuroscience*, **2010**, 30, 3675-88	6.6	76
152	Formation of aberrant phosphotau fibrillar polymers in neural cultured cells. *FEBS Journal*, **2002**, 269, 1484-9		76
151	Regulation of GSK3 isoforms by phosphatases PP1 and PP2A. *Molecular and Cellular Biochemistry*, **2010**, 344, 211-5	4.2	68
150	M1 muscarinic receptor activation protects neurons from beta-amyloid toxicity. A role for Wnt signaling pathway. *Neurobiology of Disease*, **2004**, 17, 337-48	7.5	68
149	GSK-3 inhibitors for Alzheimer's disease. *Expert Review of Neurotherapeutics*, **2007**, 7, 1527-33	4.3	64

148	Tau overexpression results in its secretion via membrane vesicles. *Neurodegenerative Diseases*, **2012**, 10, 73-5	2.3	61
147	GSK3β overexpression induces neuronal death and a depletion of the neurogenic niches in the dentate gyrus. *Hippocampus*, **2011**, 21, 910-22	3.5	61
146	The role of glycogen synthase kinase 3 in the early stages of Alzheimers' disease. *FEBS Letters*, **2008**, 582, 3848-54	3.8	61
145	The role of GSK3 in Alzheimer disease. *Brain Research Bulletin*, **2009**, 80, 248-50	3.9	59
144	Tau Phosphorylation by GSK3 in Different Conditions. *International Journal of Alzheimer's Disease*, **2012**, 2012, 578373	3.7	57
143	Novel function of Tau in regulating the effects of external stimuli on adult hippocampal neurogenesis. *EMBO Journal*, **2016**, 35, 1417-36	13	56
142	Selective alterations of neurons and circuits related to early memory loss in Alzheimer's disease. *Frontiers in Neuroanatomy*, **2014**, 8, 38	3.6	55
141	Tau Structures. *Frontiers in Aging Neuroscience*, **2016**, 8, 262	5.3	55
140	Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau. *Molecular Neurodegeneration*, **2007**, 2, 17	19	54
139	Neuronal apoptosis and reversible motor deficit in dominant-negative GSK-3 conditional transgenic mice. *EMBO Journal*, **2007**, 26, 2743-54	13	54
138	New Features about Tau Function and Dysfunction. *Biomolecules*, **2016**, 6,	5.9	54
137	Zeta 14-3-3 protein favours the formation of human tau fibrillar polymers. *Neuroscience Letters*, **2004**, 357, 143-6	3.3	53
136	Extracellular Monomeric Tau Is Internalized by Astrocytes. *Frontiers in Neuroscience*, **2019**, 13, 442	5.1	52
135	GSK-3 Mouse Models to Study Neuronal Apoptosis and Neurodegeneration. *Frontiers in Molecular Neuroscience*, **2011**, 4, 45	6.1	49
134	Quinones facilitate the self-assembly of the phosphorylated tubulin binding region of tau into fibrillar polymers. *Biochemistry*, **2004**, 43, 2888-97	3.2	49
133	Tau protein and adult hippocampal neurogenesis. *Frontiers in Neuroscience*, **2012**, 6, 104	5.1	48
132	Biochemical, ultrastructural, and reversibility studies on huntingtin filaments isolated from mouse and human brain. *Journal of Neuroscience*, **2004**, 24, 9361-71	6.6	47
131	Taurine, an inducer for tau polymerization and a weak inhibitor for amyloid-beta-peptide aggregation. *Neuroscience Letters*, **2007**, 429, 91-4	3.3	44

130	Novel connection between newborn granule neurons and the hippocampal CA2 field. *Experimental Neurology*, **2015**, 263, 285-92	5.7	43
129	Propagation of Tau via Extracellular Vesicles. *Frontiers in Neuroscience*, **2019**, 13, 698	5.1	43
128	The ubiquitin-proteasome system in Huntington's disease. *Neuroscientist*, **2005**, 11, 583-94	7.6	42
127	Dual effects of increased glycogen synthase kinase-3β activity on adult neurogenesis. *Human Molecular Genetics*, **2013**, 22, 1300-15	5.6	41
126	Function of tau protein in adult newborn neurons. *FEBS Letters*, **2009**, 583, 3063-8	3.8	41
125	Tau in neurodegenerative diseases: tau phosphorylation and assembly. *Neurotoxicity Research*, **2004**, 6, 477-82	4.3	39
124	Peripherally triggered and GSK-3β driven brain inflammation differentially skew adult hippocampal neurogenesis, behavioral pattern separation and microglial activation in response to ibuprofen. *Translational Psychiatry*, **2014**, 4, e463	8.6	38
123	Proteins and microRNAs are differentially expressed in tear fluid from patients with Alzheimer's disease. *Scientific Reports*, **2019**, 9, 15437	4.9	37
122	GSK3 inhibitors and disease. *Mini-Reviews in Medicinal Chemistry*, **2009**, 9, 1024-9	3.2	37
121	Lithium, a potential protective drug in Alzheimer's disease. *Neurodegenerative Diseases*, **2008**, 5, 247-9	2.3	37
120	Tau aggregates and tau pathology. *Journal of Alzheimer's Disease*, **2008**, 14, 449-52	4.3	36
119	Effect of quinones on microtubule polymerization: a link between oxidative stress and cytoskeletal alterations in Alzheimer's disease. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2005**, 1740, 472-80	6.9	36
118	Enhanced induction of the immunoproteasome by interferon gamma in neurons expressing mutant Huntingtin. *Neurotoxicity Research*, **2004**, 6, 463-8	4.3	36
117	GSK-3 dependent phosphoepitopes recognized by PHF-1 and AT-8 antibodies are present in different tau isoforms. *Neurobiology of Aging*, **2003**, 24, 1087-94	5.6	36
116	Tau phosphorylation, aggregation, and cell toxicity. *Journal of Biomedicine and Biotechnology*, **2006**, 2006, 74539		35
115	Characteristics of the binding of thioflavin S to tau paired helical filaments. *Journal of Alzheimer's Disease*, **2006**, 9, 279-85	4.3	35
114	Testing the ubiquitin-proteasome hypothesis of neurodegeneration in vivo. *Trends in Neurosciences*, **2004**, 27, 66-9	13.3	33
113	Thermodynamics of the interaction between Alzheimer's disease related tau protein and DNA. *PLoS ONE*, **2014**, 9, e104690	3.7	29

112	Lithium as a Treatment for Alzheimer's Disease: The Systems Pharmacology Perspective. *Journal of Alzheimer's Disease*, **2019**, 69, 615-629	4.3	28
111	Tau Spreading Mechanisms; Implications for Dysfunctional Tauopathies. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	28
110	Neurotoxic dopamine quinone facilitates the assembly of tau into fibrillar polymers. *Molecular and Cellular Biochemistry*, **2005**, 278, 203-12	4.2	28
109	Decreased glycogen synthase kinase-3 levels and activity contribute to Huntington's disease. *Human Molecular Genetics*, **2015**, 24, 5040-52	5.6	27
108	Cognitive Decline in Neuronal Aging and Alzheimer's Disease: Role of NMDA Receptors and Associated Proteins. *Frontiers in Neuroscience*, **2017**, 11, 626	5.1	27
107	Tau isoform with three microtubule binding domains is a marker of new axons generated from the subgranular zone in the hippocampal dentate gyrus: implications for Alzheimer's disease. *Journal of Alzheimer's Disease*, **2012**, 29, 921-30	4.3	27
106	Different susceptibility to neurodegeneration of dorsal and ventral hippocampal dentate gyrus: a study with transgenic mice overexpressing GSK3□*PLoS ONE*, **2011**, 6, e27262	3.7	24
105	Sources of extracellular tau and its signaling. *Journal of Alzheimer's Disease*, **2014**, 40 Suppl 1, S7-S15	4.3	22
104	Kidins220 accumulates with tau in human Alzheimer's disease and related models: modulation of its calpain-processing by GSK3/PP1 imbalance. *Human Molecular Genetics*, **2013**, 22, 466-82	5.6	22
103	Tau phosphorylation in hippocampus results in toxic gain-of-function. *Biochemical Society Transactions*, **2010**, 38, 977-80	5.1	21
102	Assembly in vitro of tau protein and its implications in Alzheimer's disease. *Current Alzheimer Research*, **2004**, 1, 97-101	3	21
101	Role of tau N-terminal motif in the secretion of human tau by End Binding proteins. *PLoS ONE*, **2019**, 14, e0210864	3.7	20
100	Phosphorylation modulates the alpha-helical structure and polymerization of a peptide from the third tau microtubule-binding repeat. *Biochimica Et Biophysica Acta - General Subjects*, **2005**, 1721, 16-26	4	20
99	Intracellular and extracellular microtubule associated protein tau as a therapeutic target in Alzheimer disease and other tauopathies. *Expert Opinion on Therapeutic Targets*, **2016**, 20, 653-61	6.4	19
98	The role of the VQIVYK peptide in tau protein phosphorylation. *Journal of Neurochemistry*, **2007**, 103, 1447-60	6	19
97	Decreased adult neurogenesis in hibernating Syrian hamster. *Neuroscience*, **2016**, 333, 181-92	3.9	18
96	A Simple Model to Study Tau Pathology. *Journal of Experimental Neuroscience*, **2016**, 10, 31-8	3.6	18
95	Induction of paclitaxel resistance by the Kaposi's sarcoma-associated herpesvirus latent protein LANA2. *Journal of Virology*, **2008**, 82, 1518-25	6.6	18

94	In Vivo Reprogramming Ameliorates Aging Features in Dentate Gyrus Cells and Improves Memory in Mice. *Stem Cell Reports*, **2020**, 15, 1056-1066	8	18
93	ACE2 is on the X chromosome: could this explain COVID-19 gender differences?. *European Heart Journal*, **2020**, 41, 3095	9.5	17
92	GSK3 Overexpression in Dentate Gyrus Neural Precursor Cells Expands the Progenitor Pool and Enhances Memory Skills. *Journal of Biological Chemistry*, **2016**, 291, 8199-213	5.4	17
91	Sulfo-glycosaminoglycan content affects PHF-tau solubility and allows the identification of different types of PHFs. *Brain Research*, **2002**, 935, 65-72	3.7	17
90	Identification of nitric oxide synthases in isolated bovine brain vessels. *Neuroscience Research*, **1996**, 25, 195-9	2.9	17
89	Secretion of full-length tau or tau fragments in a cell culture model. *Neuroscience Letters*, **2016**, 634, 63-69	3.3	17
88	Changes in tau phosphorylation in hibernating rodents. *Journal of Neuroscience Research*, **2013**, 91, 954-62	4.4	16
87	In vitro tau fibrillization: mapping protein regions. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2006**, 1762, 683-92	6.9	16
86	Bi-directional genetic modulation of GSK-3 exacerbates hippocampal neuropathology in experimental status epilepticus. *Cell Death and Disease*, **2018**, 9, 969	9.8	16
85	The involvement of cholinergic neurons in the spreading of tau pathology. *Frontiers in Neurology*, **2013**, 4, 74	4.1	15
84	Microtubule depolymerization and tau phosphorylation. *Journal of Alzheimer's Disease*, **2013**, 37, 507-13	4.3	15
83	Calpain-mediated truncation of GSK-3 in post-mortem brain samples. *Journal of Neuroscience Research*, **2009**, 87, 1156-61	4.4	15
82	Looking for novel functions of tau. *Biochemical Society Transactions*, **2012**, 40, 653-5	5.1	15
81	Memantine inhibits calpain-mediated truncation of GSK-3 induced by NMDA: implications in Alzheimer's disease. *Journal of Alzheimer's Disease*, **2009**, 18, 843-8	4.3	15
80	Mass spectrometric identification and structural analysis of the third-generation synthetic cannabinoids on the UK market since the 2013 legislative ban. *Forensic Toxicology*, **2017**, 35, 376-388	2.6	14
79	Phospho-Tau Changes in the Human CA1 During Alzheimer's Disease Progression. *Journal of Alzheimer's Disease*, **2019**, 69, 277-288	4.3	14
78	Adenosine receptor-induced second messenger production in adult guinea-pig cerebellum. *British Journal of Pharmacology*, **1993**, 110, 1085-90	8.6	13
77	MicroRNA-22 Controls Aberrant Neurogenesis and Changes in Neuronal Morphology After Status Epilepticus. *Frontiers in Molecular Neuroscience*, **2018**, 11, 442	6.1	13

76	Argyrophilic grain pathology as a natural model of tau propagation. *Journal of Alzheimer's Disease*, **2014**, 40 Suppl 1, S123-33	4.3	12
75	Expression of frontotemporal dementia with parkinsonism associated to chromosome 17 tau induces specific degeneration of the ventral dentate gyrus and depressive-like behavior in mice. *Neuroscience*, **2011**, 196, 215-27	3.9	12
74	Tau as a molecular marker of development, aging and neurodegenerative disorders. *Current Aging Science*, **2008**, 1, 56-61	2.2	12
73	Forskolin and 3-isobutyl-1-methylxanthine increase basal and sodium nitroprusside-elevated cyclic GMP levels in adult guinea-pig cerebellar slices. *Journal of Neurochemistry*, **1994**, 62, 2212-8	6	12
72	Nuclear localization of beta-catenin in adult mouse thalamus correlates with low levels of GSK-3beta. *NeuroReport*, **1999**, 10, 2699-703	1.7	12
71	Dual mechanism of phosphatidylinositol hydrolysis by substance P in brain. *FEBS Journal*, **1988**, 172, 547-52		12
70	Differences Between Human and Murine Tau at the N-terminal End. *Frontiers in Aging Neuroscience*, **2020**, 12, 11	5.3	11
69	Excitotoxic inactivation of constitutive oxidative stress detoxification pathway in neurons can be rescued by PKD1. *Nature Communications*, **2017**, 8, 2275	17.4	11
68	Calpain regulates N-terminal interaction of GSK-3β with 14-3-3β, p53 and PKB but not with axin. *Neurochemistry International*, **2011**, 59, 97-100	4.4	11
67	Differences in structure and function between human and murine tau. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2019**, 1865, 2024-2030	6.9	10
66	Coenzyme q induces tau aggregation, tau filaments, and Hirano bodies. *Journal of Neuropathology and Experimental Neurology*, **2008**, 67, 428-34	3.1	10
65	Molecular forms of butyrylcholinesterase in rat brain microvessels. *Neuroscience Letters*, **1990**, 120, 46-9	3.3	10
64	Tau-positive nuclear indentations in P301S tauopathy mice. *Brain Pathology*, **2017**, 27, 314-322	6	9
63	Intra- and extracellular protein interactions with tau. *Current Alzheimer Research*, **2010**, 7, 670-6	3	9
62	Secretion of full-length Tau or Tau fragments in cell culture models. Propagation of Tau in vivo and in vitro. *Biomolecular Concepts*, **2018**, 9, 1-11	3.7	9
61	TNAP Plays a Key Role in Neural Differentiation as well as in Neurodegenerative Disorders. *Sub-Cellular Biochemistry*, **2015**, 76, 375-85	5.5	8
60	Glycogen synthase kinase-3β regulates fractalkine production by altering its trafficking from Golgi to plasma membrane: implications for Alzheimer's disease. *Cellular and Molecular Life Sciences*, **2017**, 74, 1153-1163	10.3	8
59	Hippocampal neuronal subpopulations are differentially affected in double transgenic mice overexpressing frontotemporal dementia and parkinsonism linked to chromosome 17 tau and glycogen synthase kinase-3beta. *Neuroscience*, **2008**, 157, 772-80	3.9	8

58	Transgenic mouse models with tau pathology to test therapeutic agents for Alzheimer's disease. *Mini-Reviews in Medicinal Chemistry*, **2002**, 2, 51-8	3.2	8
57	Endothelin stimulates protein phosphorylation in blood-brain barrier. *Biochemical and Biophysical Research Communications*, **1996**, 219, 366-9	3.4	8
56	Tau and neuron aging **2013**, 4, 23-8		8
55	A mouse model to study tau pathology related with tau phosphorylation and assembly. *Journal of the Neurological Sciences*, **2007**, 257, 250-4	3.2	7
54	Validation of Suspected Somatic Single Nucleotide Variations in the Brain of Alzheimer's Disease Patients. *Journal of Alzheimer's Disease*, **2017**, 56, 977-990	4.3	6
53	Phospho-Tau Accumulation and Structural Alterations of the Golgi Apparatus of Cortical Pyramidal Neurons in the P301S Tauopathy Mouse Model. *Journal of Alzheimer's Disease*, **2017**, 60, 651-661	4.3	6
52	Alzheimer disease-like cellular phenotype of newborn granule neurons can be reversed in GSK-3β overexpressing mice. *Molecular Psychiatry*, **2013**, 18, 395	15.1	6
51	Testing the possible inhibition of proteasome by direct interaction with ubiquitylated and aggregated huntingtin. *Brain Research Bulletin*, **2007**, 72, 121-3	3.9	6
50	Natriuretic peptide-induced cyclic GMP accumulation in adult guinea-pig cerebellar slices. *British Journal of Pharmacology*, **1994**, 113, 216-20	8.6	6
49	Focal cerebral ischemia induces changes in oligodendrocytic tau isoforms in the damaged area. *Glia*, **2020**, 68, 2471-2485	9	5
48	Alternative neural circuitry that might be impaired in the development of Alzheimer disease. *Frontiers in Neuroscience*, **2015**, 9, 145	5.1	5
47	Characterization of Alzheimer paired helical filaments by electron microscopy. *Microscopy Research and Technique*, **2005**, 67, 121-5	2.8	5
46	Peripheral nervous system effects in the PS19 tau transgenic mouse model of tauopathy. *Neuroscience Letters*, **2019**, 698, 204-208	3.3	4
45	GSK3β overexpression driven by GFAP promoter improves rotarod performance. *Brain Research*, **2019**, 1712, 47-54	3.7	4
44	Tauopathy Analysis in P301S Mouse Model of Alzheimer Disease Immunized With DNA and MVA Poxvirus-Based Vaccines Expressing Human Full-Length 4R2N or 3RC Tau Proteins. *Vaccines*, **2020**, 8,	5.3	4
43	New Beginnings in Alzheimer's Disease: The Most Prevalent Tauopathy. *Journal of Alzheimer's Disease*, **2018**, 64, S529-S534	4.3	4
42	Frontotemporal Dementia-Associated N279K Tau Mutation Localizes at the Nuclear Compartment. *Frontiers in Cellular Neuroscience*, **2018**, 12, 202	6.1	4
41	Tau kinase I overexpression induces dentate gyrus degeneration. *Neurodegenerative Diseases*, **2010**, 7, 13-5	2.3	4

40	Endothelin inhibits histamine-induced cyclic AMP accumulation in bovine brain vessels. *Microvascular Research*, **2000**, 60, 49-54	3.7	4
39	Endothelin-1 increases isoprenaline-enhanced cyclic AMP levels in cerebral cortex. *Regulatory Peptides*, **2000**, 88, 41-6		4
38	Further studies on the mechanism of action of substance P in rat brain, involving selective phosphatidylinositol hydrolysis. *Neurochemical Research*, **1995**, 20, 1147-53	4.6	4
37	Involvement of calcium in phosphoinositide metabolism in the blood-brain barrier. *Cellular Signalling*, **1995**, 7, 261-7	4.9	4
36	Endothelin-1 stimulates myristoylated alanine-rich C-kinase substrate (MARCKS) phosphorylation in rat cerebellar slices. *Neuroscience Letters*, **1995**, 194, 53-6	3.3	4
35	Temperature effects on cholinesterases from rat brain capillaries. *Bioscience Reports*, **1986**, 6, 573-7	4.1	4
34	Excitotoxicity induced by kainic acid provokes glycogen synthase kinase-3 truncation in the hippocampus. *Brain Research*, **2015**, 1611, 84-92	3.7	3
33	Commentary: Genome-wide association study identifies 74 loci associated with educational attainment. *Frontiers in Molecular Neuroscience*, **2017**, 10, 23	6.1	3
32	Specific profile of tau isoforms in argyrophylic grain disease. *Journal of Experimental Neuroscience*, **2013**, 7, 51-9	3.6	3
31	Heterogeneity of beta-adrenoceptors in guinea-pig brain: radioligand binding and cyclic nucleotide generation. *Journal of Neurochemistry*, **1997**, 68, 2610-7	6	3
30	Nitric oxide mediates the PAF-stimulated cyclic GMP production in hippocampal slices. *Biochemical and Biophysical Research Communications*, **1996**, 226, 27-31	3.4	3
29	Regulation of phosphoinositide cycle by intracellular sodium in the blood-brain barrier. *Cellular Signalling*, **1996**, 8, 387-92	4.9	3
28	Tetrahydroaminoacridine affects the cholinergic function of blood-brain barrier. *Life Sciences*, **1993**, 53, 1165-72	6.8	3
27	Dissociation between secretion and protein phosphorylation in agonist-stimulated platelets; action of PCA-4230, a new antithrombotic drug. *Thrombosis Research*, **1994**, 75, 121-32	8.2	3
26	Overexpression of GSK-3β in Adult Tet-OFF GSK-3β Transgenic Mice, and Not During Embryonic or Postnatal Development, Induces Tau Phosphorylation, Neurodegeneration and Learning Deficits. *Frontiers in Molecular Neuroscience*, **2020**, 13, 561470	6.1	3
25	Protein Biomarkers for the Diagnosis of Alzheimer's Disease at Different Stages of Neurodegeneration. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	3
24	A new non-aggregative splicing isoform of human Tau is decreased in Alzheimer's disease. *Acta Neuropathologica*, **2021**, 142, 159-177	14.3	3
23	Tau triggers tear secretion by interacting with muscarinic acetylcholine receptors in New Zealand white rabbits. *Journal of Alzheimer's Disease*, **2014**, 40 Suppl 1, S71-7	4.3	2

22	Tau Phosphorylation. *Advances in Neurobiology*, **2011**, 73-82	2.1	2
21	Endothelin enhances adenosine and isoprenaline elevated cyclic AMP levels in rat cerebellar slices. *Peptides*, **1999**, 20, 1115-22	3.8	2
20	Profiling of Argonaute-2-loaded microRNAs in a mouse model of frontotemporal dementia with parkinsonism-17. *International Journal of Physiology, Pathophysiology and Pharmacology*, **2018**, 10, 172-183	2.4	2
19	Tau Protein as a New Regulator of Cellular Prion Protein Transcription. *Molecular Neurobiology*, **2020**, 57, 4170-4186	6.2	2
18	Neuronal models for studying tau pathology. *International Journal of Alzheimer's Disease*, **2010**, 2010,	3.7	1
17	Binding of tau protein to the ends of ex vivo paired helical filaments. *Journal of Alzheimer's Disease*, **2008**, 13, 177-85	4.3	1
16	Protein phosphorylation in the blood-brain barrier. Possible presence of MARCKS in brain microvessels. *Neurochemistry International*, **1996**, 28, 59-65	4.4	1
15	Microtubule-associated protein tau in murine kidney: role in podocyte architecture.. *Cellular and Molecular Life Sciences*, **2022**, 79, 97	10.3	1
14	p38 Inhibition Decreases Tau Toxicity in Microglia and Improves Their Phagocytic Function.. *Molecular Neurobiology*, **2022**, 59, 1632	6.2	1
13	Role of polyglycine repeats in the regulation of glycogen synthase kinase activity. *Protein and Peptide Letters*, **2008**, 15, 586-9	1.9	1
12	Human Brain Single Nucleotide Polymorphism: Validation of DNA Sequencing. *Journal of Alzheimer's Disease Reports*, **2018**, 2, 103-109	3.3	1
11	TNAP upregulation is a critical factor in Tauopathies and its blockade ameliorates neurotoxicity and increases life-expectancy.. *Neurobiology of Disease*, **2022**, 165, 105632	7.5	0
10	p38 activation occurs mainly in microglia in the P301S Tauopathy mouse model.. *Scientific Reports*, **2022**, 12, 2130	4.9	0
9	Glycolysis and gluconeogenesis: A teaching view. *Journal of Biological Chemistry*, **2021**, 296, 100016	5.4	0
8	CPEB alteration and aberrant transcriptome-polyadenylation lead to a treatable SLC19A3 deficiency in Huntington's disease. *Science Translational Medicine*, **2021**, 13, eabe7104	17.5	0
7	Boronate-tau mediated uptake in neurons. *Journal of Alzheimer's Disease*, **2014**, 40, 143-51	4.3	
6	B24 Huntington's Disease As A Tauopathy. *Journal of Neurology, Neurosurgery and Psychiatry*, **2014**, 85, A17-A17	5.5	
5	Centro de Biologia Molecular "Severo Ochoa": a center for basic research into Alzheimer's disease. *Journal of Alzheimer's Disease*, **2010**, 21, 325-35	4.3	

4 GSK-3, a Key Player in Alzheimer's Disease105-124

3 Animal Models with Modified Expression of GSK-3 for the Study of Its Physiology and of Its Implications in Human Pathologies203-219

2 Phosphorylation, Microtubule Binding and Aggregation of Tau Protein in Alzheimer's Disease **2001**, 601-607

1 Co-expression of FTDP-17 Human Tau and GSK-3β (or APPSW) in Transgenic Mice: Induction of Tau Polymerization and Neurodegeneration **2008**, 337-342